Inflammatory Bowel Disease: The role of commensal microbiome in immune regulation Wah M, Vázquez MAM, Padilla FJB Published Sep 2021, in the gastroenterology & hepatology
The incidence of inflammatory bowel disease (IBD) is increasing. Microbiome is one of the most important factors in its development and affects the different clinical outcomes of IBD patients depending on its composition and different alterations. We conducted a systematic review to discuss the association between microbiome and IBD in terms of immune regulation, and therapies that can modify microbiota. A comprehensive systematic literature search was performed through April 2020 in PubMed, Web of Science, the Cochrane Library, and clinicaltrials.gov. Inclusion criteria required IBD immune regulation and alternate therapeutics for IBD. This analysis helps explain the multifactorial origin of microbiome diversity including normal immune regulation, immune pathophysiology of IBD, and shows the evidence of several therapeutic targets to change microbiome in patients with IBD, such as prebiotics, probiotics, antibiotics, fecal microbiota transplant, and others.
Keywords: Enfermedad inflamatoria intestinal; Inflammatory bowel disease; Microbioma; Microbiome; Microbiota; Microbiota transplantation; Trasplante microbiota.